Through our highly experienced ADC Research & Development Team, we are building a pipeline of class-leading ADCs with superior therapeutic index (TI) for difficult-to-treat cancers.
Our approach is to develop the best ADC for any given target or tumor sub-type rather than 'technology-driven ADCs'.
All our ADCs incorporate tumor-selective release & activation of the most relevant payload according to mechanism, optimizing anti-cancer efficacy and enhancing patient safety.
Multi-platform approach to deliver the best ADC for any given target and tumor indication.
Optimal ADC design requires a variety of platforms combined with expert knowledge to piece all elements together.
Iksuda has built a team of experts in ADC drug development and design. We have learned from the past and continue to innovate – we don’t let ADC dogma get in the way of progress.
Building a successful pipeline of Best in Class ADCs requires experience-based integration of multiple components to achieve high probability of success.
Collaborative, flexible and informed; Iksuda offers advice, guidance and support during agreed work programs to ensure the best ADC against any given target.
I am thrilled to be working with Iksuda because of our commitment to lead the crowd, not follow it
ADC Design Principles
Building a successful ADC pipeline requires experience-based integration of multiple components to achieve a high probability of success. Iksuda ensures the optimal delivery of the most appropriate payload MoA for any given target and tumor; all programs incorporate tumor-selective payload release & activation.
ADC Design Strategy
Building superior ADCs
Iksuda ADCs are designed for maximum anti-cancer impact and market leading TI, for patients that, today, have few effective treatment options.
Tumor Selective Payload Activation
Precision targeting of the optimal payload MOA
Iksuda incorporates highly advanced tumor-selective cleavable linkers in all its ADCs for improved safety.
Optimal Payload Choices
Multiple payload series with known and novel mechanisms
Iksuda matches the most appropriate payload MOA to the target and tumor for maximum anti-cancer efficacy.
Simple, scalable solutions to ADC instability
Stable bioconjugation is fundamental to ADC design. Iksuda uses proprietary and in-licensed technologies for the stable bioconjugation to wild-type or engineered antibodies.
Groundbreaking science delivered by expert teams
The quality of our people defines our business. Our people are given the freedom to innovate, alongside the guidance and support that comes with being part of a collaborative team.